Jefferies raises NeoGenomics price target to $21
Bullish analyst revision with meaningful implied upside, but a target alone does not establish a catalyst or guarantee performance.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Bullish analyst revision with meaningful implied upside, but a target alone does not establish a catalyst or guarantee performance.
What happened, with direct paths to the underlying reporting
Jefferies raised its NEO target from $16.50 to $21, about 23% above the posted price of $17.03. The sizable revision supports a bullish view, while remaining an analyst opinion.
Target: $21
Posted price: $17.03
Analyst firm: Jefferies
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.